WCM/NYP Partners with LLS to Host Blood Cancer Survivorship Event

Thanks to a valued partnership with the Leukemia and Lymphoma Society (LLS), Weill Cornell Medicine and NewYork-Presbyterian Hospital (WCM/NYP) were proud co-hosts of “Life Beyond Blood Cancer,” a free educational event for patients and caregivers. The program explored various aspects of survivorship as experienced by people with lymphoma, leukemia, myeloma and other blood cancers.

The event drew in nearly 100 members of the New York metropolitan area’s blood cancer community for an evening of shared information and inspiration. Speakers included a range of experts across the WCM/NYP cancer care team, as well as blood cancer survivors who shared their experience and insight into living with Hodgkin lymphoma, chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

Here are a few highlights:

WCM/NYP Lymphoma Program Chief Dr. Peter Martin explained that innovative advancements in personalized medicine, immunotherapy, and targeted therapy have positively influenced blood cancer survival rates. Almost 1.5 million people in the United States are living with lymphoma, leukemia or myeloma. Dr. Martin noted that as patients are living longer, more clinical attention should be focused on treating the whole patient and his/her needs, as opposed to treating just the cancer cells within the body.

Alan Astrow, Chief of Hematology and Oncology at NewYork-Presbyterian Brooklyn Methodist Hospital, explained that a cancer diagnosis can affect a patient’s life in ways that exceed the strictly medical, and many patients welcome discussion about their spiritual, religious and existential concerns. Dr. Astrow advocated for increased communication between physicians and patients regarding spiritual needs, since a clear understanding of a patient’s hopes, fears and values can provide guidance when making decisions in the face of medical uncertainty.

Kelly Trevino, PhD, a clinical psychologist at WCM/NYP with a specialization in psychosocial oncology, discussed strategies for managing the anxiety that often accompanies a cancer diagnosis. Threatening situations like cancer can lead to worry and nervousness, muscle tension, shortness of breath, tingling/numbness and difficulty concentrating – all of which can have a negative impact on quality of life. Coping strategies include deep breathing, progressive muscle relaxation, pursuit of distracting activities and even scheduled “worry time” to prevent anxious thoughts from infiltrating the entire day.

Three survivors across varying ages and diagnoses then shared the ups and downs of their treatment and post-treatment journeys and provided the audience with insight into life beyond cancer.

We at Weill Cornell Medicine and NewYork-Presbyterian Hospital are honored to be able to offer educational programs and resources to people affected by cancer, and we are committed to doing our best to address the needs of our patient community throughout all stages of the cancer journey.

LLS
The event concluded with an interactive question-and-answer session between the speakers and audience, moderated by WCM/NYP outpatient oncology social worker Susan Marchal, LCSW.

 

Novel Therapy Approved for Previously Untreated Hodgkin Lymphoma Patients

The United States Food and Drug Administration (FDA) recently approved brentuximab vedotin in combination with chemotherapy as a first-line treatment for people with advanced-stage classical Hodgkin lymphoma.

Also known as Adcetris, brentuximab vedotin is an antibody drug conjugate that targets the CD30 protein present on lymphoma cells and delivers a toxin designed to promote cancer cell death. The drug has been previously approved to treat systemic anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma that has returned after prior therapy.

The FDA’s approval follows the encouraging results of the phase III ECHELON-1 clinical trial, presented at the 2017 American Society of Hematology (ASH) Meeting and Exposition and published in the New England Journal of Medicine. The trial, which was open at Weill Cornell Medicine and NewYork-Presbyterian Hospital, compared standard therapy with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) versus adriamycin, vinblastine and dacarbazine plus brentuximab vedotin (A+AVD).

Of the 1,300+ enrolled patients, those receiving A+AVD were demonstrated to be 23 percent less likely to experience disease progression, a need for additional therapy, or death, as compared to the cohort receiving the standard of care therapy.

Weill Cornell Medicine
Dr. Peter Martin

“ABVD has been the standard therapy for a couple decades because it works really well, but it’s great to have new treatments available for people with Hodgkin lymphoma,” said Peter Martin, Chief of the Lymphoma Program. “I’m proud that we were able to offer this treatment at Weill Cornell a long time ago through the ECHELON-1 trial. Like any treatment, the A+AVD combination may not be right for everyone and requires consideration of side effects, like infection risk and neuropathy. Decisions between patients and physicians regarding the best treatment should follow an open discussion of the evidence.”